EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of multidrug resistance in tumors using 99mTc-doxorubicin

Bianca Gutfilen, Sergio Augusto Lopes de Souza, Thiago Barboza, Bruna Fortunato Novis, Claudia Lopes Rodrigues Chagas, Maria Verônica Fonseca Torres de Oliveira, Vivian M. Rumjanek

Advances in Radiotherapy & Nuclear Medicine · 2024

DOI: 10.36922/arnm.2822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Radiotherapy & Nuclear Medicine, 2024. Verfasst von Bianca Gutfilen und 6 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (DOX) is a potent chemotherapeutic agent used as the first-choice drug in treating different types of cancer, such as leukemia, lymphoma, and breast cancer, among others. However, the development of multidrug resistance represents a significant obstacle to the successful treatment of tumors. In this study, we assessed whether labeled DOX could be uptaken by susceptible and multidrug-resistant cell lines and by tumors in vivo in animals. The efficiency of DOX labeling was maintained at around 90% in this work. To evaluate the effect of 99mTc-DOX on cells expressing active P-glycoprotein (Pgp), we utilized cultured human chronic myeloid leukemia K562 cells and the resistant counterpart Lucena 1 cells. Lucena 1 cell line showed overexpression of Pgp that was not observed in K562. Our results suggested that the resistance to labeled or unlabeled DOX can be reversed by Pgp inhibition and can be easily detected. In conclusion, administering 99mTc-DOX into mice enables the differentiation between multidrug-resistant tumors in a non-invasive way and the evaluation of tumor resistance and possible chemosensitizers.

Zitieren

APA

Gutfilen, B., Souza, S. A. L. D., Barboza, T., Novis, B. F., Chagas, C. L. R., Oliveira, M. V. F. T. D., & Rumjanek, V. M. (2024). Evaluation of multidrug resistance in tumors using 99mTc-doxorubicin. Advances in Radiotherapy & Nuclear Medicine. https://doi.org/10.36922/arnm.2822

Vancouver

Gutfilen B, Souza SALD, Barboza T, Novis BF, Chagas CLR, Oliveira MVFTD, et al. Evaluation of multidrug resistance in tumors using 99mTc-doxorubicin. Advances in Radiotherapy & Nuclear Medicine. 2024. doi:10.36922/arnm.2822

BibTeX
@article{Gutfilen2024,
  author = {Gutfilen, Bianca and Souza, Sergio Augusto Lopes de and Barboza, Thiago and Novis, Bruna Fortunato and Chagas, Claudia Lopes Rodrigues and Oliveira, Maria Verônica Fonseca Torres de and Rumjanek, Vivian M.},
  title = {Evaluation of multidrug resistance in tumors using 99mTc-doxorubicin},
  journal = {Advances in Radiotherapy & Nuclear Medicine},
  year = {2024},
  doi = {10.36922/arnm.2822}
}
Kostenlos starten →